Crohn's and Colitis Conference: A Patient and Provider Point of Care Conference
Crohn’s Disease and Ulcerative Colitis are the two subtypes of Inflammatory Bowel Disease (IBD) and are the special focus of the Inflammatory Bowel Disease Program. Our Program offers state-of-the-art, evidence-based, integrated patient care.
Over one million adults and approximately 100,000 children in the United States have IBD; as many as 70,000 (this is updated number according to CCF) new cases of IBD are diagnosed annually.
IBD impacts many facets of a patient’s life – our program includes a team-based approach to ensure that these various areas are addressed.
Our multidisciplinary IBD Team consists of IBD-focused gastroenterologists, colorectal surgeons, radiologists, pathologists and a dietician.
We aim to provide high quality care, focusing on a personalized treatment approach for each of our patients with the goal of improving our patients’ quality of life. Our cutting-edge research has helped us more optimally utilize current drug therapies and have been instrumental in the delivery of once novel therapies to mainstream
Target Audience
- Gastroenterologists
- Physician assistants
- Nurse practitioners
- Nurses
- Internal Medicine physicians
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Review current guidelines for the management of Ulcerative Colitis
- Summarize the evidence on current biologic drugs in IBD
- Discuss the evidence of the efficacy and safety of biologic monotherapy in IBD
- Review the evidence on the efficacy and safety of combination therapy in IBD
- Plan targets of medical therapy in IBD and specify how to achieve and adjust them
- Relate the evidence on the efficacy and safety of dietary modification and diet therapy in IBD
- Assess different approaches to IBD complications
- Apply current algorithms in the management of Crohn’s disease
- Detect complications that can develop after colectomy for ulcerative colitis
- Discuss surgical approaches for perianal Crohn’s disease
8:00-8:05 AM
Welcome and Introduction
8:05-8:25
Why did I get IBD? Genetic and Environmental Risk Factors of IBD
Joshua Noe, MD
8:25-8:45
Why do I have so much joint pain all the time? IBD Related Arthritis
Richard Hariman, MD
8:45-9:05
What is the best therapy for my Crohn’s disease? State of the Art Treatment of Crohn’s Disease
Andres Yarur, MD
9:05-9:25
What is the best therapy for my Ulcerative Colitis? State of the Art Treatment in Ulcerative Colitis
Amir Patel, MD
9:35-9:55
Do I have to take medications for the rest of my life? Now that I feel well can I stop my medications?
Daniel Stein, MD
9:55-10:15
What kind of diet should I be eating? Diet and Inflammatory Bowel Disease
Mandi Stayner, RD
10:15-10:35
What happens if I do not get treated for my IBD? – The natural history of IBD
Poonam Beniwal-Patel, MD
10:45-11:05
Are these medications going to give me cancer? Risk of IBD and Treatment Related Malignancy
Lilani Perera, MD
11:05-11:25
Will I have an ostomy for the rest of my life? Colostomy, Ileostomy management in IBD.
Timothy Ridolfi, MD
11:25-11:45
When will I be ready to make the transition to an adult gastroenterologist? Transition of care from pediatric to adult gastroenterology.
Abdul ElKadri, MD
Upon entering the Health Research Center, walk through the lobby towards the left hand side. Turn left as you walk past the elevators, and follow the hall as it turns right. Follow the hallway until the end and take a right, the Alumni Center & registration will be visible *Please note: directional signs will also be posted
Poonam Beniwal-Patel, MD
Assistant Professor of Medicine
Division of Gastroenterology and Hepatology
Abdul ElKadri, MD
Assistant Professor of Pediatrics
Division of Pediatric Gastroenterology
Richard Hariman, MD
Associate Professor
Medical Director, Froedtert Rheumatology Clinic
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Andres Yarur, MD
Assistant Professor of Medicine
Division of Gastroenterology and Hepatology
All persons in control of content have NO relevant financial relationships to disclose except the following:
Name | Company | Role |
Daniel Stein, MD | AbbVie | Speaker/consulting |
Janssen | speaker | |
Takeda | speaker | |
Andres Yarur, MD | AbbVie | Speakers bureau |
Prometheus | speaker | |
Takeda | Advisory board | |
Poonam Beniwal-Patel, MD | Takeda |
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following and in accordance with the ACCME® standards for Commercial Support Number 6, these relationships were reviewed via the MCW conflict of interest resolution process and resolved.
ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this Live activity for a maximum of 3.25 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 3.25 hours of participation for continuing education for allied health professionals.
AANP Accreditation Statement:
The Medical College of Wisconsin is accredited by the American Association of Nurse Practitioners as an approved provider of nurse Practitioner continuing education. Provider Number: 150930.
AANP CE Statement:
Medical College of Wisconsin, Inc. is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 150930. This program has been approved for 3.25 contact hours of continuing education (which includes 0.0 hours of pharmacology).
Available Credit
- 3.25 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 3.25 Hours of ParticipationHours of Participation credit.
- 3.25 NP Contact Hours